Talquetamab vs Real-World Physician's Choice in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-Cell Maturation Antigen Therapy: Analyses of MonumenTAL-1 vs LocoMMotion/MoMMent

被引：0

作者：

Mateos Manteca, Maria-Victoria ^{[1
]}

Jakubowiak, Andrzej ^{[2
]}

Einsele, Hermann ^{[3
]}

Schinke, Carolina ^{[4
]}

Besemer, Britta ^{[5
]}

Anguille, Sebastien ^{[6
]}

Manier, Salomon ^{[7
]}

Rasche, Leo ^{[8
]}

Goldschmidt, Hartmut ^{[9
]}

van de Donk, Niels ^{[10
,11
]}

Perrot, Aurore ^{[12
]}

Teipel, Raphael ^{[13
]}

Karlin, Lionel ^{[14
]}

Scheid, Christof ^{[15
]}

San-Miguel, Jesus ^{[16
]}

Pawlyn, Charlotte ^{[17
,18
]}

Martinez-Lopez, Joaquin ^{[19
]}

Cavo, Michele ^{[20
]}

Diels, Joris ^{[21
]}

Renaud, Thomas ^{[22
]}

Orel, Oleksiy ^{[23
]}

Cabrieto, Jedelyn ^{[21
]}

Perualila, Nolen ^{[21
]}

Weisel, Katja ^{[24
]}

Moreau, Philippe ^{[25
]}

机构：

[1] Univ Hosp Salamanca, Inst Biomed Res Salamanca IBSAL, CIBERONC, Salamanca, Spain

[2] Univ Chicago, Chicago, IL USA

[3] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[4] Univ Arkansas Med Sci, Myeloma Ctr, Little Rock, AR USA

[5] Univ Tubingen, Tubingen, Germany

[6] Univ Antwerp, Antwerp Univ Hosp, Ctr Cell Therapy & Regenerat Med, Vaccine & Infect Dis Inst, Antwerp, Belgium

[7] Univ Lille, CHU Lille, Lille, France

[8] Univ Hosp Wurzburg, Wurzburg, Germany

[9] Univ Hosp Heidelberg, GMMG Study Grp, Dept Internal Med 5, Heidelberg, Germany

[10] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Hematol, Amsterdam, Netherlands

[11] Canc Ctr Amsterdam, Amsterdam, Netherlands

[12] Univ Toulouse, Serv Hematol, Toulouse, France

[13] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, Dresden, Germany

[14] Ctr Hosp Lyon Sud, Lyon, France

[15] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[16] Clin Univ Navarra, Navarra, Spain

[17] Inst Canc Res, London, England

[18] Royal Marsden NHS Fdn Trust, London, England

[19] Univ Complutense Madrid, CNIO Clin Res Unit H12O, CIBERONC, Dept Hematol,Hosp 12 Octubre, Madrid, Spain

[20] Univ Bologna, IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[21] Janssen Pharmaceut NV, Beerse, Belgium

[22] Janssen Res & Dev, Raritan, NJ USA

[23] Janssen Cilag GmbH, Neuss, Germany

[24] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[25] Univ Hosp Hotel Dieu, Hematol Dept, Beirut, Lebanon

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-050

引用

页码：S69 / S70

页数：2

共 50 条

[11] Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Ye, Jing Christine
Biran, Noa
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Ammann, Eric
Renaud, Thomas
Kane, Colleen
Parekh, Trilok
Gray, Kathleen
Peterson, Steve
Costa, Luciano J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (02) : 124 - 134.e5
[12] Comparative efficacy of teclistamab versus real-world physician's choice of therapy in the prospective LocoMMotion study in patients with triple-class exposed relapsed/refractory multiple myeloma
van de Donk, Niels W. C. J.
Moreau, Philippe
Delforge, Michel
Einsele, Hermann
Ghilotti, Francesca
Diels, Joris
Elsada, Ahmed
Strulev, Vadim
Pei, Lixia
Kobos, Rachel
Smit, Jennifer
Marshall, Alexander
Slavcev, Mary
Weisel, Katja
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S33 - S34
[13] Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study
Sanchez, Larysa
Schinke, Carolina
Krishnan, Amrita
Berdeja, Jesus G.
de Donk, Niels W. C. J. van
Mateos, Maria Victoria
Chari, Ajai
Parekh, Samir
Mouhieddine, Tarek H.
Jagannath, Sundar
Bahlis, Nizar J.
Touzeau, Cyrille
Oriol, Albert
San-Miguel, Jesus
Otero, Paula Rodriguez
Minnema, Monique C.
Campagna, Michela
Masterson, Tara J.
Hilder, Brandi W.
Tolbert, Jaszianne
Renaud, Thomas
Gray, Kathleen
Smit, Damiette
Heuck, Christoph
Rasche, Leo
BLOOD, 2023, 142
[14] Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
Krishnan, Amrita
Nooka, Ajay K.
Chari, Ajai
Garfall, Alfred L.
Martin, Thomas G.
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok
Marshall, Alexander
Slavcev, Mary
Usmani, Saad Z.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (06)
[15] Comparative effectiveness of teclistamab versus real-world physician's choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma
Krishnan, Amrita
Nooka, Ajay
Chari, Ajai
Garfall, Alfred
Martin, Thomas
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok
Marshall, Alexander
Slavcev, Mary
Usmani, Saad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S174 - S174
[16] Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naive in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
Mammadzadeh, Aytaj
Peng, Fulei
Atrash, Shebli
Hashmi, Hamza
Mohan, Meera
Alkharabsheh, Omar
Afrough, Aimaz
Cui, Wei
Mahmoudjafari, Zahra
Abdallah, Al-Ola
BLOOD, 2022, 140 : 4277 - 4278
[17] Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
Lal, Bhavesh Mohan
Pandey, Toshali
Alzubi, Marah
Alrawabdeh, Jawad
Shaughnessy Jr, John D.
Zhan, Fenghuang
Siegel, Eric
Schinke, Carolina
Thanendrarajan, Sharmilan
Zangari, Maurizio
van Rhee, Frits
Al Hadidi, Samer
BLOOD, 2024, 144 : 2405 - 2406
[18] Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive review
Yashar, David
Regidor, Bernard
Goldwater, Marissa-Skye
Bujarski, Sean
Del Dosso, Ashley
Berenson, James R.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
[19] Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma
Kumar, Shaji
Fu, Alan
Niesvizky, Ruben
Jagannath, Sundar
Boccia, Ralph
Raje, Noopur
BLOOD ADVANCES, 2021, 5 (02) : 367 - 376
[20] Clinical updates of B-cell maturation antigen-targeted therapy in multiple myeloma (MM) and relapsed/refractory MM (Review)
Xing, Rui
Wang, Meidan
Wang, Liqun
Pan, Mingyue
Wang, Yixi
Zhou, Hongwei
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2025, 55 (02)

← 1 2 3 4 5 →